Market Research Report

A quick peek into the report

1.1    Scope of the Study
         1.2    Research Methodology
         1.3    Data Sources
         1.4    Assumptions and Limitations
         1.5    Data and Prediction Modeling

2.1    Introduction
         2.2    NGS Technologies and Applications
         2.3    NGS Approaches in Clinical Diagnostics
         2.4    NGS Technology Trends
         2.5    Regulations and Compliances

3.1    NGS Industry
         3.2    Addressable Market and Growth Potential, 2019 and 2028
                  3.2.1    North America
                  3.2.2    Europe
                  3.2.3    Asia-Pacific
                  3.2.4    Latin America
                  3.2.5    Rest-of-the-World

4.1    Mergers and Acquisitions
         4.2    Product Launches and Developments
         4.3    Synergistic Activities
         4.4    Business Expansion Activities and Others
         4.5    Patent Analysis
                  4.5.1    Overview

5.1    Overview
         5.2    Impact Analysis
         5.3    Market Drivers
                  5.3.1    Growing Demand for Non-Invasive Diagnosis
                  5.3.2    Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
                  5.3.3    Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
                  5.3.4    Technological Advancements in the Field of Computational Biology
         5.4    Market Restraints
                  5.4.1    Lack of Use of Available Data for Drug Development Initiatives
                  5.4.2    Lack of High Complexity Testing Centers
                  5.4.3    Expensive Sequencing Procedures and Their Applications in Medical Treatments
                  5.4.4    High Capital Requirement Hampering the Expansion of Global Reach
         5.5    Market Opportunities
                  5.5.1    Massive Scope for Adoption of NGS-Based Monitoring and Diagnostic Test in Emerging Nations
                  5.5.2    Technological Advancements in Molecular Techniques and Diagnostic Tests
                  5.5.3    Hybridization of Technologies
                  5.5.4    Rise of Direct-to-Consumer (DTC) Testing Services

6.1    Overview
         6.2    Reproductive Health
                  6.2.1    Non-Invasive Prenatal Tests
                  6.2.2    Newborn Screening
                  6.2.3    IVF
                              6.2.3.1    Primary Benefits of NGS Used in IVF
         6.3    Oncology
         6.4    Rare Disease Diagnostics
         6.5    Cardiovascular
         6.6    Other Applications

7.1    Overview
         7.2    Commercial Assays/Tests
         7.3    Laboratory Developed Tests
         7.4    Direct to Consumer Test
         7.5    Pre-Commercial Tests

8.1    Overview
         8.2    Single Read Sequencing
         8.3    Whole Exome Sequencing
         8.4    Whole Genome Sequencing
         8.5    Other Sequencing Methods

9.1    Overview
         9.2    Out-Patient Clinics/General Practitioners
         9.3    Diagnostic Centers
         9.4    Hospitals
         9.5    Other End Users

10.1    Overview
           10.2    North America
                      10.2.1    U.S.
                      10.2.2    Canada
           10.3    Europe
                      10.3.1    Germany
                      10.3.2    France
                      10.3.3    U.K.
                      10.3.4    Italy
                      10.3.5    Spain
                      10.3.6    Netherlands
                      10.3.7    Russia
                      10.3.8    Rest-of-Europe
            10.4    Asia-Pacific
                       10.4.1    China
                       10.4.2    Japan
                       10.4.3    Australia
                       10.4.4    India
                       10.4.5    South Korea
                       10.4.6    Singapore
                       10.4.7    Rest-of-APAC
            10.5    Latin America
                       10.5.1    Brazil
                       10.5.2    Mexico
                       10.5.3    Rest-of-Latin America
            10.6    Rest-of-the-World

11.1 Market Share Analysis
11.2 Growth Share Analysis

12.1    Overview
           12.2     Agilent Technologies, Inc.
                       12.2.1    Company Overview
                       12.2.2    Role of Agilent Technologies, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.2.3    Financials
                       12.2.4    Key Insights about Financial Health of the Company
                       12.2.5    SWOT Analysis
            12.3    Ancestry.com LLC
                       12.3.1    Company Overview
                       12.3.2    Role of Ancestry.com LLC in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.3.3    SWOT Analysis
            12.4    ArcherDX, Inc.
                       12.4.1    Company Overview
                       12.4.2    Role of ArcherDX, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.4.3    SWOT Analysis
            12.5    Beijing Genomics Institute (BGI)
                       12.5.1    Company Overview
                       12.5.2    Role of BGI in the in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.5.3    SWOT Analysis
             12.6   Cancer Genetics, Inc.
                       12.6.1    Company Overview
                       12.6.2    Role of Cancer Genetics, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.6.3    Financials
                       12.6.4    Key Insights about Financial Health of the Company
                       12.6.5    SWOT Analysis
            12.7    CENTOGENE AG
                       12.7.1    Company Overview
                       12.7.2    Role of CENTOGENE AG in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.7.3    SWOT Analysis
            12.8    F. Hoffmann-La Roche Ltd
                       12.8.1    Company Overview
                       12.8.2    Role of F. Hoffmann-La Roche Ltd in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.8.3    Financials
                       12.8.4    Key Insights about Financial Health of the Company
                       12.8.5    SWOT Analysis
            12.9    GenePath Dx
                       12.9.1    Company Overview
                       12.9.2    Role of GenePath DX, in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.9.3    SWOT Analysis
            12.10   Illumina, Inc.
                       12.10.1    Company Overview
                       12.10.2    Role of Illumina, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                       12.10.3    Financials
                       12.10.4    Key Insights about Financial Health of the Company
                       12.10.5    SWOT Analysis
            12.11   Laboratory Corporation of America Holdings
                        12.11.1    Company Overview
                        12.11.2    Role of Laboratory Corporation of America Holdings in the Global NGS-Based Monitoring and Diagnostic Market
                        12.11.3    Financials
                        12.11.4    SWOT Analysis
            12.12   Myriad Genetics, Inc.
                        12.12.1    Company Overview
                        12.12.2    Role of Myriad Genetics, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                        12.12.3    Financials
                        12.12.4    SWOT Analysis
             12.13  QIAGEN N.V.
                        12.13.1    Company Overview
                        12.13.2    Role of QIAGEN N.V. in the Global NGS-Based Monitoring and Diagnostic Test Market
                        12.13.3    Financials
                        12.13.4    Key Insights about Financial Health of the Company
                        12.13.5    SWOT Analysis
             12.14   Quest Diagnostics Incorporated
                         12.14.1    Company Overview
                         12.14.2    Role of Quest Diagnostics Incorporated in the Global NGS-Based Monitoring and Diagnostic Test Market
                         12.14.3    Financials
                         12.14.4    SWOT Analysis
             12.15   Siemens Healthineers, Inc.
                         12.15.1    Company Overview
                         12.15.2    Role of Siemens Healthineers, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                         12.15.3    Financials
                         12.15.4    Key Insights about Financial Health of the Company
                         12.15.5    SWOT Analysis
              12.16   Thermo Fisher Scientific Inc.
                          12.16.1    Company Overview
                          12.16.2    Role of Thermo Fisher Scientific Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
                          12.16.3    Financials
                          12.16.4    Key Insights about Financial Health of the Company
                          12.16.5    SWOT Analysis
              12.17   HTG Molecular Diagnostics, Inc.
                          12.17.1    Company Overview
                          12.17.2    Role of HTG Molecular Diagnostics, Inc. in the Global NGS-Based Monitoring and Diagnostic Test Market
               12.18   Vela Diagnostics Pte. Ltd.
                           12.18.1    Company Overview
                           12.18.2    Role of Vela Diagnostics Pte. Ltd. in the Global NGS-Based Monitoring and Diagnostic Test Market

Table 2.1:    Regulatory Bodies
Table 5.1:    Impact Analysis of Market Drivers
Table 5.2:    Impact Analysis of Market Restraints

Figure 1:    Impact of Market Drivers and Market Restraints on the Global NGS-Based Monitoring and Diagnostic Test Market
Figure 2:    Global NGS-Based Monitoring and Diagnostic Test Market Snapshot, 2018 and 2028 ($Million)
Figure 3:    Dominating Segments of the Global NGS-Based Monitoring and Diagnostic Test Market, 2018 and 2028
Figure 4:    Global NGS-Based Monitoring and Diagnostic Test Market (by Method), 2018 and 2028
Figure 5:    Global NGS-Based Monitoring and Diagnostic Test Market (by Application), 2018 and 2028
Figure 6:    Global NGS-Based Monitoring and Diagnostic Test Market (by Type), 2018 and 2028
Figure 7:    Global NGS-Based Monitoring and Diagnostic Test Market (by End User), 2018 and 2028
Figure 8:    Global NGS-Based Monitoring and Diagnostic Test Market (by Region), 2018 and 2028
Figure 1.1:    Global NGS-Based Monitoring and Diagnostic Test Market Segmentation
Figure 1.2:    Global NGS-Based Monitoring and Diagnostic Test Market Research Methodology
Figure 1.3:    Primary Research
Figure 1.4:    Secondary Research
Figure 1.5:    Data Triangulation
Figure 1.6:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 1.7:    Top-Down Approach (Segment-Wise Analysis)
Figure 1.8:    Assumptions and Limitations
Figure 1.9:    Considered Factors for Data Prediction and Modeling
Figure 2.1:    Different steps in Next-Generation Sequencing Technology
Figure 2.2:    Evolution of Next-Generation Sequencers with Progress in Molecular Technologies
Figure 3.1:    North America NGS-Based Monitoring and Diagnostic Test Addressable Market, 2019 and 2028
Figure 3.2:    Europe NGS-Based Monitoring and Diagnostic Test Addressable Market 2019 and 2028
Figure 3.3:    Asia-Pacific NGS-Based Monitoring and Diagnostic Test Addressable Market, 2019 and 2028
Figure 3.4:    Latin America NGS-Based Monitoring and Diagnostic Test Addressable Market 2019 and 2028
Figure 4.1:    Share of Key Developments and Strategies, January 2016 – June 2019
Figure 4.2:    Product Launches Share (by Company), January 2016 – June 2019
Figure 4.3:    Synergistic Activities Share (by Company), January 2016 – June 2019
Figure 4.4:    Business Expansion Activities Share (by Company), January 2016 – June 2019
Figure 4.5:    Share of Patents (by Ownership), 2016-2019
Figure 5.1:    Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 5.2:    Number of Deaths (in Millions) by Different Forms of Cancer, 2018
Figure 5.3:    Benefits of Multiplexing Reactions
Figure 6.1:    Global NGS-Based Monitoring and Diagnostic Test Market (by Application)
Figure 6.2:    Global NGS-Based Monitoring and Diagnostic Test Market (by Application), 2018 and 2028
Figure 6.3:    Global NGS-Based Monitoring and Diagnostic Test Market (by Reproductive Health), 2018-2028
Figure 6.4:    Global NGS-Based Monitoring and Diagnostic Test Market (by NIPT), 2018-2028
Figure 6.5:    Global NGS-Based Monitoring and Diagnostic Test Market (by Newborn Screening), 2018-2028
Figure 6.6:    Global NGS-Based Monitoring and Diagnostic Test Market (by IVF),2018-2028
Figure 6.7:    Global NGS-Based Monitoring and Diagnostic Test Market (by Oncology), 2018-2028
Figure 6.8:    Global NGS-Based Monitoring and Diagnostic Test Market (by Rare Disease Diagnostics), 2018-2028
Figure 6.9:    Global NGS-Based Monitoring and Diagnostic Test Market (by Cardiovascular), 2018-2028
Figure 6.10:    Global NGS-Based Monitoring and Diagnostic Test Market (by Other Applications), 2018-2028
Figure 7.1:    Global NGS-based Monitoring and Diagnostic Test Market (by Type)
Figure 7.2:    Global NGS-based Monitoring and Diagnostic Test Market (by Type), 2018 and 2028
Figure 7.3:    Global NGS-Based Monitoring and Diagnostic Test Market (by Commercial Assays/Tests), 2018-2028
Figure 7.4:    Global NGS-Based Monitoring and Diagnostic Test Market (by Laboratory Developed Test), 2018-2028
Figure 7.5:    Global NGS-Based Monitoring and Diagnostic Test Market (by Direct to Consumer Test), 2018-2028
Figure 7.6:    Global NGS-Based Monitoring and Diagnostic Test Market (by Pre-Commercial Tests), 2018-2028
Figure 8.1:    Global NGS-Based Monitoring and Diagnostic Test Market (by Method)
Figure 8.2:    Global NGS-Based Monitoring and Diagnostic Test Market (by Method), 2018 and 2028
Figure 8.3:    Global NGS-Based Monitoring and Diagnostic Test Market (by Single Read Sequencing), 2018-2028
Figure 8.4:    Global NGS-Based Monitoring and Diagnostic Test Market (by Whole Exome Sequencing), 2018-2028
Figure 8.5:    Global NGS-Based Monitoring and Diagnostic Test Market (by Whole Genome Sequencing), 2018-2028
Figure 8.6:    Global NGS-Based Monitoring and Diagnostic Test Market (by Other Sequencing Methods), 2018-2028
Figure 9.1:    Global NGS-Based Monitoring and Diagnostic Test Market (by End User)
Figure 9.2:    Global NGS-Based Monitoring and Diagnostic Test Market (by End User), 2018 and 2028
Figure 9.3:    Global NGS-Based Monitoring and Diagnostic Test Market (by Out-Patient Clinics/GPs), 2018-2028
Figure 9.4:    Global NGS-Based Monitoring and Diagnostic Test Market (by Diagnostic Centers), 2018-2028
Figure 9.5:    Global NGS-Based Monitoring and Diagnostic Test Market (by Hospitals), 2018-2028
Figure 9.6:    Global NGS-Based Monitoring and Diagnostic Test Market (by Other End Users), 2018-2028
Figure 10.1:    Global NGS-Based Monitoring and Diagnostic Test Market (by Region), 2018 and 2028
Figure 10.2:    Global NGS-Based monitoring and Diagnostic Test Market (by Region), 2018-2028
Figure 10.3:    Global NGS-Based Monitoring and Diagnostic Test Market Share (by Region), 2018
Figure 10.4:    Global NGS-Based Monitoring and Diagnostic Test Market Share (by Region), 2028
Figure 10.5:    North America NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.6:    North America: Market Dynamics
Figure 10.7:    North America NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
Figure 10.8:    U.S. NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.9:    Canada NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.10:    Europe NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.11:    Europe: Market Dynamics
Figure 10.12:    Europe NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
Figure 10.13:    Germany NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.14:    France NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.15:    The U.K. NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.16:    Italy NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.17:    Spain NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.18:    Netherlands NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.19:    Russia NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.20:    Rest-of-Europe NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.21:    Asia-Pacific NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.22:    APAC: Market Dynamics
Figure 10.23:    APAC NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
Figure 10.24:    China NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.25:    Japan NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.26:    Australia NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.27:    India NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.28:    South Korea NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.29:    Singapore NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.30:    RoAPAC NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.31:    Latin America NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.32:    Latin America: Market Dynamics
Figure 10.33:    Latin America NGS-Based Monitoring and Diagnostic Test Market (by Country), 2018-2028
Figure 10.34:    Brazil NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.35:    Mexico NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.36:    Rest-of-Latin America NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 10.37:    RoW NGS-Based Monitoring and Diagnostic Test Market, 2018-2028
Figure 11.1:    Market Share Analysis for the Global NGS-Based Monitoring and Diagnostic Test Market, 2018
Figure 11.2:    Growth Share Matrix for Global NGS-Based Monitoring and Diagnostic Test Market (by Company), 2018
Figure 12.1:    Total Number of Companies Profiled
Figure 12.2:    Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.3:    Agilent Technologies, Inc.: Overall Financials, 2016-2018
Figure 12.4:    Agilent Technologies, Inc.: Revenue (by Segment), 2016-2018
Figure 12.5:    Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
Figure 12.6:    Agilent Technologies, Inc.: R&D Expenditure, 2016-2018
Figure 12.7:    Agilent Technologies, Inc.: SWOT Analysis
Figure 12.8:    Ancestry.com LLC: Overall Product Portfolio
Figure 12.9:    Ancestry.com LLC: SWOT Analysis
Figure 12.10:    Ancestry.com LLC: Overall Product Portfolio
Figure 12.11:    ArcherDX, Inc.: SWOT Analysis
Figure 12.12:    BGI: Overall Product Portfolio
Figure 12.13:    BGI: SWOT Analysis
Figure 12.14:    Product Portfolio: Cancer Genetics, Inc.
Figure 12.15:    Cancer Genetics, Inc.: Overall Financials, 2016-2018
Figure 12.16:    Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
Figure 12.17:    Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
Figure 12.18:    Cancer Genetics, Inc.: SWOT Analysis
Figure 12.19:    CENTOGENE AG: Overall Product Portfolio
Figure 12.20:    CENTOGENE AG: SWOT Analysis
Figure 12.21:    F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 12.22:    F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 12.23:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 12.24:    F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 12.25:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 12.26:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 12.27:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 12.28:    GenePath DX: Overall Product Portfolio
Figure 12.29:    GenePath DX: SWOT Analysis
Figure 12.30:    Illumina, Inc.: Overall Product Portfolio
Figure 12.31:    Illumina, Inc.: Overall Financials, 2016-2018
Figure 12.32:    Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 12.33:    Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 12.34:    Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 12.35:    Illumina, Inc.: SWOT Analysis
Figure 12.36:    Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 12.37:    Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 12.38:    Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 12.39:    Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 12.40:    Laboratory Corporation of America Holdings: SWOT Analysis
Figure 12.41:    Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.42:    Myriad Genetics, Inc.: Overall Financials, 2016-2018
Figure 12.43:    Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
Figure 12.44:    Myriad Genetics, Inc.: SWOT Analysis
Figure 12.45:    QIAGEN N.V.: Overall Product Portfolio
Figure 12.46:    QIAGEN N.V.: Overall Financials, 2016-2018
Figure 12.47:    QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 12.48:    QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 12.49:    QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 12.50:    QIAGEN N.V.: SWOT Analysis
Figure 12.51:    Product Portfolio: Quest Diagnostics Incorporated
Figure 12.52:    Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 12.53:    Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
Figure 12.54:    Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.55:    Siemens Healthineers, Inc.: Overall Product Portfolio
Figure 12.56:    Siemens Healthineers, Inc.: Overall Financials, 2016-2018
Figure 12.57:    Siemens Healthineers, Inc.: Revenue (by Segment), 2016-2018
Figure 12.58:    Siemens Healthineers, Inc.: Revenue (by Region), 2016-2018
Figure 12.59:    Siemens Healthineers, Inc.: R&D Expenditure, 2016-2018
Figure 12.60:    Siemens Healthineers, Inc.: SWOT Analysis
Figure 12.61:    Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.62:    Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 12.63:    Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 12.64:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 12.65:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 12.66:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 12.67:    HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 12.68:    Vela Diagnostic Pte. Ltd.: Overall Product Portfolio

Report Description

Scope of the Market Intelligence on NGS Based Monitoring and Diagnostic Test Market

The NGS based monitoring and diagnostic test research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global NGS based monitoring and d9iganostic test market.

Market Segmentation

The NGS based monitoring and diagnostic test market segmentation (on the basis of manufacturing) is further segmented into application, method, type and end user.

The NGS based monitoring and diagnostic test market segmentation (on the basis of application) is segmented into reproductive health, oncology, rare disease diagnostic, cardiovascular, and other applications.

The NGS based monitoring and diagnostic test market segmentation (on the basis of method) is segmented into single read sequencing, whole exome sequencing, whole exome sequencing, and other methods.

The NGS based monitoring and diagnostic test market segmentation (on the basis of type) is segmented into commercial assay, laboratory developed tests, direct to consumer and pre commercial test.

Key Companies in the NGS Based Monitoring and Diagnostic Test Market

The key manufacturers who have been contributing significantly to the NGS Based Monitoring and Diagnostic Test market include Agilent Technologies, Inc., Ancestry.com LLC, ArcherDX, Inc.,Beijing Genomics Institute, Cancer Genetics, Inc.,Centogene AG, F. Hoffmann-La Roche Ltd, GenePath DX, illumina Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers, Inc., and Thermo Fisher Scientific Inc. among others.

Key Questions Answered in this Report:

•   What are the major market drivers, challenges, and opportunities in the global NGS based monitoring and diagnostic test market?
•   What are the underlying structures resulting in the emerging trends within the global NGS based monitoring and diagnostic test market?
•   How is each segment of the global NGS based monitoring and diagnostic test market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2028?
•   What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2028?
•   What are the key applications in the global NGS based monitoring and diagnostic test market? What are the major segments of these applications?
•   Who are the key manufacturers the global NGS based monitoring and diagnostic test, and what are their contributions?

Market Overview

Global NGS based Monitoring and Diagnostic Test Market Forecast, 2019-2028

The NGS based monitoring and diagnostic test Industry analysis by BIS Research projects the market to grow at a significant CAGR of 18.08% during the forecast period, 2019-2028. The NGS based monitoring and diagnostic test market generated $3,354.8 million revenue in 2018, in terms of value.

The NGS based monitoring and diagnostic test market growth has been primarily attributed to the major drivers in this market such as increasing prevalence of cancer and infectious diseases, rising number of test-based diagnostics for NGS based monitoring and diagnostic tests, steady investment and consolidation in the market and favorable regulatory environment. However, there are significant challenges which are restraining the market growth. These challenges include high cost of treatments and complexity of the treatments.

Expert Quote

“The development field has achieved huge success over the past year with regulatory approval of test in the U.S., Europe, Japan and Australia proving the potential these tests have to successfully cure patients around the globe.”